Chimeric antigen receptors on the surface of an engineered T-cell - Stock image

Blood, Cancer - Illness, Leukemia, Germany, Antibody

Chimeric antigen receptors on the surface of an engineered T-cell royalty-free stock photo
Chimeric antigen receptors on the surface of an engineered T-cell royalty-free stock photo

{{ t('more_than_one_credit', { zero: calc.totalCreditCost }) }}{{ t('one_credit') }}

This video clip is being converted to HD

Once this video clip is done converting, you'll be able to download it from your video conversion queue or download history.

Add licenses

Licenses
Credits


{{step.title}}

This image is for editorial use only? Editorial use only photos don't have any model or property releases, which means they can't be used for commercial, promotional, advertorial or endorsement purposes. This type of content is intended to be used in connection with events that are newsworthy or of general interest (for example, in a blog, textbook, newspaper or magazine article).
Included with your subscription
Your download will be saved to your Dropbox.
This format requires conversion? This format requires a quick conversion (usually under 5 mins) before download begins, or you can get the largest and smallest formats immediately.
  1. {{mapSizeToLabelTag(size)}}
{{size.description}}
{{step.reasonForBox}}
Please contact your administrator.


How would you like to pay?



Not sure what license you need? Learn more >
Download not working? Get it here.To download it locally, get it here.
You've already downloaded this file.

Includes our standard license.
Add an extended license.

Largest size:{{calc.largestSizeAvailable.description}}
Stock photo ID:951540058
Upload date:April 26, 2018

Description

CARs are engineered cell receptors that allow T cells to recognize and attack cancer cells in a specific way. They are built by connecting several functional parts from different proteins. In this image a signal protein (ZAP70) is attached to the intracellular domain.
Incredible stock. Flexible pricing. Buy credits or subscribe today.